

16 June 2023

OKYO Pharma Limited

("OKYO" or "Company")

US Registration Statement Effective

Further to the Dealing Announcement published by the FCA on 22 May 2023, the board of directors of OKYO Pharma Limited (NASDAQ: OKYO), is delighted to announce that the SEC have granted effectiveness of the Company's F-1 filing, allowing the shares formally held by shareholders outside of the US to be capable of unrestricted trading on the NASDAQ market.

Information for holders through CREST

Following the share consolidation (which will take place on the Delisting Date), holders of the Company's ordinary shares in CREST received a CDI (a CREST depository interest issued by Euroclear) into their CREST account, with each CDI representing one new ordinary share. The CDIs can now be freely exchanged for the underlying ordinary shares within the CREST system and all restrictions or cross-border exchanges have been lifted

Information for holders in certificated form

For persons who currently hold Ordinary Shares in certificated form, these shareholders will shortly receive a "DRS Statement" from the Company's US transfer agent. The DRS Statement will explain how to dematerialise the underlying shares into a trading account. Please note that as each new ordinary share results from a 65 into 1 share consolidation, the holding on the DRS will represent the former certificated holdings divided by a factor of 65 and rounded down to the nearest whole share. **You do not need to return your original share certificate to the Company.**

Enquiries:

OKYO Pharma Limited	Gary S. Jacob, Chief Executive Officer	+44 (0)20 7495 2379
----------------------------	--	---------------------

Investor Relations	Paul Spencer	+44 (0)20 7495 2379
---------------------------	--------------	---------------------